<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1997
-----------------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 0-14991
---------
LIFE TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 34-0431300
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
9800 MEDICAL CENTER DRIVE, ROCKVILLE, MD 20850
(Address of principal executive offices) (Zip Code)
--------------------------------
Registrant's telephone number, including area code: (301) 610-8000
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.01 Par Value
----------------------------
(Title of each class)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes x No
----- -----
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ x ]
The aggregate market value of the voting stock held by non-affiliates of the
registrant as of February 20, 1998 was $353,741,283.
The number of shares of Common Stock outstanding as of February 20, 1998 was
23,476,546.
Documents Incorporated By Reference
Portions of the registrant's definitive Proxy Statement for its Annual Meeting
of Stockholders to be held on April 14, 1998 are incorporated by reference in
Part III of this Report.
<PAGE>
As used herein, the terms "LTI" and the "Company" shall mean Life Technologies,
Inc. and its subsidiaries unless the context otherwise indicates and the term
"Proxy Statement" shall mean the definitive Proxy Statement for the Company's
Annual Meeting of Stockholders to be held on April 14, 1998.
PART I
------
ITEM 1. BUSINESS
- ------- --------
GENERAL
-------
LTI, originally incorporated in Ohio in 1915 and reincorporated in Delaware in
1986, develops, manufactures and supplies more than 3,000 products used in life
sciences research and commercial manufacture of genetically engineered products.
The Company's products include sera, other cell growth media, biochemicals and
enzymes and other biological products necessary for recombinant DNA procedures.
These and related products and services provided by the Company are used in
cellular biochemistry and molecular biology research and in the production of
genetically engineered pharmaceuticals such as interferons, interleukins and
tissue plasminogen activator ("t-PA").
The Company's products are sold to more than 20,000 customers consisting of
laboratories generally associated with universities, medical research centers,
and government institutions as well as biotechnology, pharmaceutical, energy,
agricultural and chemical companies. The Company sells its products principally
through its own direct sales organization which is supplemented by a network of
distributors.
The Company's activities are focused on the following areas:
o PRODUCTS FOR LIFE SCIENCES RESEARCH
CELL CULTURE PRODUCTS - The Company is a leading supplier of sera and
other cell and tissue culture media used by life sciences researchers to
grow cells under laboratory conditions.
CELL AND MOLECULAR BIOLOGY PRODUCTS - The Company is a leading supplier of
enzymes, nucleic acids, custom primers, reagent systems, biochemicals and
other products used by life sciences researchers to identify, isolate and
manipulate the metabolic processes and genetic material of living
organisms.
o PRODUCTS FOR COMMERCIAL PROCESSES USING GENETICALLY ENGINEERED CELLS
The Company is a leading supplier of sera, cell culture media and reagents
used for the commercial production of pharmaceuticals and other materials
made by genetically engineered cells. This use of the Company's products
is also referred to as "industrial bioprocessing".
MARKETS
-------
The Company serves two principal markets: life sciences research and commercial
manufacture of genetically engineered products.
The life sciences research market consists of laboratories generally associated
with universities, medical research centers, government institutions such as the
National Institutes of Health, and other research
1
<PAGE>
institutions as well as biotechnology, pharmaceutical, energy, agricultural and
chemical companies.
Life sciences researchers require special biochemical research tools capable of
performing precise functions in a given experimental procedure. The Company
serves two principal disciplines of the life sciences research market: cellular
biochemistry and molecular biology.
Cellular biochemistry involves the study of the genetic functioning and
biochemical composition of cells as well as their proliferation,
differentiation, growth and death. The understanding gained from such study has
broad application in the field of developmental biology and is important in the
study of carcinogenesis, virology, immunology, vaccine design and production and
agriculture. To grow the cells required for research, researchers use cell or
tissue culture media which simulate under laboratory conditions (in vitro) the
environment which surrounds such cells naturally (in vivo) and which facilitate
their growth.
Molecular biology involves the study of the genetic information systems of
living organisms. The genetic material of living organisms consists of long,
double-stranded molecules of DNA (deoxyribonucleic acid). DNA contains the
information required for the production of proteins by means of RNA (ribonucleic
acid), a single-stranded molecule similar in structure to DNA. Proteins have
many different functional properties and include antibodies, certain hormones
and enzymes. Many researchers study the various steps of gene expression from
DNA to RNA to protein products, and the impact of these proteins on cellular
function. Other researchers are interested in manipulating the DNA-RNA system
in order to modify its functioning. Through techniques that are commonly termed
"genetic engineering" or "gene-splicing," a researcher can modify an organism's
naturally occurring DNA to produce a desired protein not usually produced by the
organism, or to produce a naturally produced protein at an increased rate.
The Company also serves industries which apply genetic engineering to the
commercial production of otherwise rare or difficult to obtain substances with
potential for significant utility. For example, in the biotechnology industry,
these substances include interferons, interleukins, t-PA and monoclonal
antibodies. The manufacturers of these materials require larger quantities of
the same sera and other cell growth media that are also purchased in smaller
quantities as research tools. Some of these new substances are manufactured in
full scale production facilities, while others are being manufactured on a pre-
production basis. Other industries involved in the commercial production of
genetically engineered products include the pharmaceutical, food processing and
agricultural industries. The Company is expanding its activities into related
new markets for its products. These include genetic and identity testing, cell
therapy and tissue engineering involving cell culture media and plant
biotechnology applications.
PRODUCTS
--------
The Company is a major supplier of cell culture products used to maintain living
cells for study in the laboratory and for the commercial production of
pharmaceuticals and other materials made by genetically engineered cells. The
Company's cell culture products consist of bovine serum, liquid and dry-powdered
culture media, balanced salt solutions, other animal sera and plant tissue
culture media. The Company also produces and markets a line of products to
assist the researcher in analyzing cellular functions in mammals and other
multicell organisms, including the growth and differentiation of cells and their
immunological response. Sales of fetal bovine serum ("FBS"),
2
<PAGE>
a major product of the Company, accounted for 13% of the Company's net sales in
1997, 14% in 1996, and 16% in 1995.
The Company is a major supplier of products used as research tools by molecular
biologists, including restriction enzymes, DNA and RNA modifying enzymes,
specialty reagents, research apparatus, nucleic acids, molecular biology systems
and custom primers.
GEOGRAPHIC AND INDUSTRY FINANCIAL INFORMATION
---------------------------------------------
Information regarding geographic financial information is contained in the
Financial Note entitled "Geographic Data" on page F-21 of this 1997 Annual
Report on Form 10-K. The Company is engaged in one line of business.
SALES AND MARKETING
-------------------
At December 31, 1997, the Company had approximately 149 employees worldwide who
were employed in direct field sales. Most of the Company's products are sold
throughout the world by its own sales employees, and the remaining products are
sold through agents or distributors.
RESEARCH AND DEVELOPMENT
------------------------
The Company believes that a strong research and product development effort is
important to its future growth. The Company's investment in research and
development was $21.3 million in 1997, $19.1 million in 1996 and $15.9 million
in 1995. R&D expenses in 1997, 1996 and 1995 were primarily directed toward
developing new products and business solutions for the Company's customers in
the life sciences research and industrial bioprocessing areas and toward
improving production processes.
The Company conducts most of its research and development activities at its own
facilities using its own personnel. At December 31, 1997, the Company had
approximately 145 employees principally engaged in research and development. The
Company's scientific staff is augmented by advisory relationships with a number
of scientists.
The Company's research and development activity is aimed at maintaining a
leadership position in providing research tools to the life sciences research
market and enhancing its market position as a supplier of products used to
manufacture genetically engineered pharmaceuticals and other materials.
COMPETITION
-----------
Only one company is known to compete with the Company in all its major product
lines, but in each product line competition is offered by a number of companies,
including companies substantially larger and with greater financial resources
than LTI. In the Company's view, competitive position in its markets is
determined by product quality, speed of delivery, technical support, price,
breadth of product line, and timely product development. The Company believes
its customers are diverse and place varying degrees of importance on the
competitive attributes listed above. While it is difficult to rank these
attributes for all its customers in aggregate, the Company believes it is well
positioned to compete in each category.
PATENTS AND LICENSES
--------------------
The Company has a number of U.S and foreign patents and has numerous pending
patent applications. In addition to its patent portfolio, the Company also
3
<PAGE>
owns other intellectual property, and on a case by case basis, the Company
grants licenses to others to use such intellectual property. The Company does
not believe that license revenue is material to its business as a whole. In
addition, it is the Company's policy to obtain nondisclosure and confidentiality
agreements from all its employees believed to have access to proprietary
information.
The Company has obtained rights to products and technologies under a number of
license agreements with universities and others. In 1997, approximately 21% of
the Company's net sales were related to products which were licensed from others
or which incorporated technologies licensed from others. The Company intends to
continue its current strategy of seeking licenses to technologies and products
from sources around the world.
CUSTOMERS
---------
LTI has no single customer for its products which it deems to be material to its
business as a whole. However, many of the Company's customers receive funding
for their research either directly or indirectly from the federal government in
the United States and from government agencies in various countries throughout
the world.
SUPPLIERS
---------
The Company buys materials for its products from many suppliers, including
certain affiliated joint ventures, and is not dependent on any one supplier or
group of suppliers. Raw materials, other than FBS, purchased from others are
generally readily available at competitive prices from a number of suppliers.
Although there is a well-established market for FBS, one of the Company's major
products, its price is unstable, and its supply could be limited because the
availability of slaughtered cattle tends to be cyclical. The Company acquires
raw FBS products from various suppliers, including affiliated joint ventures.
Some of these suppliers provide a major portion of the FBS available from a
specific geographic region, although no single supplier provides a majority of
the total FBS available to the Company.
The Company believes it maintains a quantity of FBS inventory adequate to insure
reasonable customer service levels while guarding against normal volatility in
the supply of FBS available to the Company. FBS inventory quantities can
fluctuate significantly as the Company balances varying customer demand for FBS
against fluctuating supplies of FBS available to the Company. The Company
believes it will be able to continue to acquire FBS in quantities sufficient to
meet its customers' current requirements.
GOVERNMENT REGULATION
---------------------
Certain of the Company's cell culture products are subject to regulation under
the U.S. Federal Food, Drug and Cosmetic Act with respect to testing, safety,
efficacy, marketing, labeling and other matters. In addition, the Company's
manufacturing facilities for the production of in vitro diagnostic cell culture
products are subject to periodic inspection by the U.S. Food and Drug
Administration ("FDA") and other product-oriented federal agencies and various
state and local authorities in the U.S. Such facilities are believed to be in
compliance with the requirements of the FDA's current Good Manufacturing
Practices, other federal, state and local regulations and other quality
standards such as ISO 9000.
The U.S. federal government oversees certain recombinant DNA research activities
through the National Institutes of Health Guidelines for research
4
<PAGE>
involving recombinant DNA molecules (the "NIH Guidelines"). The NIH Guidelines
prohibit or restrict certain recombinant DNA experiments, set forth levels of
biological and physical containment of recombinant DNA molecules to be met for
various types of research and require that institutional biosafety committees
approve certain experiments before they are initiated. The NIH Guidelines now
exempt most of the experiments conducted by the Company. The Company, however,
voluntarily complies with the NIH Guidelines for its molecular and cell biology
experiments. Compliance with the NIH Guidelines has not had, and the Company
does not believe it will have in the future, a material effect on the capital
expenditures, earnings or competitive position of the Company.
The Company has an Institutional Biosafety Committee, which has been approved
and certified by the NIH Office of Recombinant DNA Activities, to oversee its
laboratory practices concerning biological agents. Through training, practices,
equipment and facilities, LTI follows the NIH Guidelines' hazard classification
system recommendations for handling bacterial and viral agents, with
capabilities through biosafety level three.
In addition to the foregoing, the Company is subject to other federal, state and
local laws and ordinances applicable to its business, including the Occupational
Safety and Health Act, the Clean Water Act, the Toxic Substances Control Act,
the Clean Air Act, various statutes and regulations applicable to the use of
radioactive material, as well as national restrictions on technology transfer,
and import, export and customs regulations and similar laws and regulations in
foreign countries. In particular, the Company is subject to European
regulations regarding importation of animal-derived products such as FBS.
EMPLOYEES
---------
At December 31, 1997, the Company had approximately 1,586 full-time and 54 part-
time employees, approximately 622 of whom were employed outside the United
States. No employees are covered by a collective bargaining agreement.
Management believes that its relations with its employees are good.
ITEM 2. PROPERTIES
- ------- ----------
The Company owns or leases property at the following principal locations, each
of which contains manufacturing, storage, laboratory or office facilities:
Rockville, Maryland (Owned and leased)
Gaithersburg, Maryland (Owned and leased)
Frederick, Maryland (Owned and leased)
Glasgow area, principally Inchinnan, Scotland (Owned and leased)
Grand Island, New York (Owned)
Auckland, New Zealand (Owned and leased)
The Company owns or leases certain other properties throughout the world in
addition to the principal properties listed. The terms of the leases for
properties to which the Company is a party range in expiration dates from 1998
to 2019, and some are renewable.
Many of the Company's plants have been constructed, renovated, or expanded one
or more times during the past ten years. The Company is currently using
substantially all of its space with some space available for expansion. The
Company considers the facilities to be in a condition suitable for their current
uses. Because of expected growth in the business and due to the increasing
requirements of customers or regulatory agencies, the Company may
5
<PAGE>
need to acquire additional space or upgrade and enhance existing space during
the next five years.
Over the past several years, the Company has undertaken a facilities upgrade and
improvement program. The initial focus of this program was the Company's
manufacturing facilities in the U.S., Scotland and New Zealand. The second
phase of the facilities modernization program focused on the Company's research
and development facilities, including the new corporate R&D facility in
Rockville, Maryland. The current phase of the facilities modernization program,
now largely completed, includes the Company's corporate administrative facility
adjoining the R&D facility in Rockville, Maryland. The Company currently
believes it may spend $50-55 million for property, plant and equipment from 1998
through 2000 for expansion and normal equipment upgrade and replacement.
Additional information regarding the Company's properties is contained in the
Financial Notes entitled "Property, Plant and Equipment" and "Leases" on page F-
10 of this 1997 Annual Report on Form 10-K.
Item 3. LEGAL PROCEEDINGS
- ------- -----------------
The Company is not involved in any pending or threatened legal proceedings
(other than ordinary routine litigation incidental to its business) which the
Company believes will have a material adverse effect on the Company's financial
statements.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- ------- ---------------------------------------------------
None.
EXECUTIVE OFFICERS OF THE REGISTRANT
- ------------------------------------
The Board of Directors elects all executive officers of the Company. Each
executive officer holds his or her office until the earlier of his or her death,
resignation, removal from office or the election or appointment of his or her
successor. No family relationships exist among any of the Company's executive
officers, directors or persons nominated to serve as such. The positions held
and period during which the executive officers have served in those positions
are set forth below:
J. STARK THOMPSON, PH.D. (age: 56; years of service: 9) was elected President
and Chief Executive Officer of the Company in August 1988 and became a director
of the Company in September 1988. Prior to joining the Company, he had been
with E.I. DuPont de Nemours & Company ("DuPont") for 21 years.
THOMAS M. COUTTS (age: 53; years of service: 28) was elected Senior Vice
President and General Manager, European Division, effective March 1, 1989. Prior
thereto, he had been Vice President of Life Technologies, Europe.
JOHN V. COOPER (age 46; years of service: 6) was elected Vice President and
General Manager, America's Research Products Division, effective April 13, 1993.
Prior thereto, he held several managerial positions with the Company since
joining the Company in 1992. Prior to joining the Company, he had been a
Worldwide Business Manager in Printed Circuit Materials for DuPont.
BRIAN D. GRAVES (age: 56; years of service: 16) was elected Vice President and
General Manager, U.S. Industrial Bioproducts Division, effective July 1, 1990.
Prior thereto, he had been Vice President of Sales and Marketing, U.S. Research
Products Division, for the Company.
6
<PAGE>
TIMOTHY E. PIERCE, PH.D. (age: 56; years of service: 7) was elected Vice
President and General Manager, Asia Pacific Division, effective September 18,
1990.
JOSEPH C. STOKES, JR. (age: 50; years of service: 9) was elected Senior Vice
President and Chief Financial Officer, effective July 16, 1996. Prior thereto,
he held the position of Vice President, Finance, Secretary and Treasurer,
effective March 1, 1989.
ROSEMARY J. VERSTEEGEN, PH.D. (age: 49; years of service: 16) was elected a Vice
President of the Company on April 16, 1991. Prior thereto, she held several
managerial positions with the Company since joining the Company in 1982.
DEREK E. WOODS, PH.D. (age: 47; years of service: 2) was elected Vice President,
Research and Development on April 15, 1997, and prior thereto had served in that
position as an appointed officer since joining the Company in 1996. Prior
thereto, he worked for Johnson & Johnson in various research and business
development positions.
PART II
-------
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
- ------- -----------------------------------------------------------------
MATTERS
-------
The Company's Common Stock is quoted on The National Association of Securities
Dealers Automated Quotation System National Market under the symbol: LTEK. The
high and low sales prices for the Company's Common Stock for each quarter of
1996 and 1997 as reported by The Nasdaq Stock Market are contained in the
Financial Notes entitled "Quarterly Financial Information" on page F-20 of this
1997 Annual Report on Form 10-K.
The number of stockholders of record of the Company's Common Stock at February
20, 1998 was 553. At February 20, 1998, The Dexter Corporation owned
approximately 52% of the outstanding Common Stock of the Company.
The Company's Board of Directors has declared regular quarterly cash dividends
in each fiscal quarter since the second quarter of 1991. For the previous three
years, cash dividends declared were: $0.03-1/3 per share in each quarter of 1995
and the first quarter of 1996, $0.04 per share for the remaining three fiscal
quarters of 1996 and the first two quarters of 1997, and $0.05 per share for the
last two quarters of 1997. The Company's Board of Directors expects to consider
the declaration and payment of quarterly dividends based on future operating
results.
ITEM 6. SELECTED FINANCIAL DATA
- ------- -----------------------
This information has been derived from, and should be read in conjunction with,
the related consolidated financial statements and Management's Discussion and
Analysis of Financial Condition and Results of Operations included elsewhere in
this 1997 Annual Report on Form 10-K.
7
<PAGE>
SELECTED FINANCIAL DATA
-----------------------
(amounts in thousands, except per share data)
<TABLE>
<CAPTION>
1997 1996 1995 1994 1993
-------- -------- -------- -------- --------
<S> <C> <C> <C> <C> <C>
FOR THE YEAR
Revenues $332,808 $310,339 $272,299 $235,262 $205,616
Research and development
expenses 21,281 19,084 15,871 15,000 14,463
Gain on product line disposal - 2,569 - - -
Operating income 50,934 46,101 34,152 28,040 25,494
Net income 32,235 28,700 22,277 18,207 16,560
Capital expenditures $ 23,386 $ 42,151 $ 11,159 $ 12,123 $ 7,230
Return on average
stockholders' equity 16.5% 17.0% 15.7% 15.2% 16.0%
Average shares outstanding:
Basic 23,171 22,881 22,601 22,457 22,412
Diluted 23,945 23,504 22,929 22,607 22,636
-------- -------- -------- -------- --------
AT DECEMBER 31
Cash and cash equivalents $ 19,076 $ 15,326 $ 23,201 $ 13,246 $ 7,927
Working capital 100,927 84,196 96,761 71,255 60,228
Total assets 280,274 253,931 208,744 171,747 145,790
Long-term debt 4,564 4,668 1,451 - -
Stockholders' equity 208,724 182,919 153,925 130,129 110,000
Per share $ 8.94 $ 7.97 $ 6.76 $ 5.79 $ 4.90
Shares outstanding 23,351 22,951 22,773 22,471 22,426
-------- -------- -------- -------- --------
PER SHARE
Net income:
Basic $ 1.39 $ 1.25 $ .99 $ .81 $ .74
Diluted 1.35 1.22 .97 .81 .73
Cash dividends declared .18 .15 1/3 .13 1/3 .13 1/3 .13 1/3
Market price:
High 35 7/8 26 1/2 18 1/3 13 1/2 17 1/3
Low 24 1/4 15 1/3 11 2/3 10 10 1/2
Close 33 1/4 25 18 1/6 13 12 1/3
-------- -------- -------- -------- --------
</TABLE>
8
<PAGE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
- ------- -----------------------------------------------------------------------
OF OPERATIONS
-------------
Statements in this Annual Report on Form 10-K concerning the Company's business
outlook or future economic performance; anticipated profitability, revenues,
expenses or other financial items; and statements concerning assumptions made or
expectations as to any future events, conditions, performance or other matters,
are "forward-looking statements" as that term is defined under the Federal
Securities Laws. Forward-looking statements are subject to risks, uncertainties
and other factors which could cause actual results to differ materially from
those stated in such statements. Such risks, uncertainties and factors include,
but are not limited to, changes in government funding for life sciences
research, changes in pricing or availability of fetal bovine serum, changes in
currency exchange rates, changes and delays in new product introduction,
customer acceptance of new products, changes in government regulations, changes
in pricing or other actions by competitors and general economic conditions, as
well as other risks detailed in the Company's filings with the Securities and
Exchange Commission, including this 1997 Annual Report on Form 10-K. See in
particular the sections entitled "Business Outlook" and "1998 Cash Flows".
The information in this Item 7 should be read in conjunction with the related
consolidated financial statements and notes thereto contained elsewhere in this
1997 Annual Report on Form 10-K.
GENERAL
The Company develops, manufactures, and sells cell and molecular biology
products and cell culture products under the GIBCO BRL brand name. Cell and
molecular biology products are used by scientists to identify, isolate, and
manipulate the metabolic processes and genetic material of living organisms.
Cell culture products include cell and tissue culture media, reagents, fetal
bovine serum ("FBS"), a major product of the Company, other animal sera, growth
and attachment factors, and plasticware. These products are used by scientists
to grow cells under laboratory conditions and are also used for the commercial
manufacture of pharmaceuticals and other life sciences products.
RESULTS OF OPERATIONS
REVENUES
The major product line components of net sales for 1997, 1996 and 1995 compare
as follows:
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996 1995
-------- -------- --------
<S> <C> <C> <C>
Cell and molecular biology $158,340 $141,189 $118,090
Cell culture 172,627 168,266 154,142
-------- -------- --------
Net sales $330,967 $309,455 $272,232
======== ======== ========
</TABLE>
Net sales for 1997 were $331.0 million, an increase of $21.5 million, or 7%,
over 1996. Sales of products other than FBS increased $35.5 million, or 13%,
when comparing 1997 net sales with 1996 and excluding the effect of changes due
to different currency translation rates. FBS sales were $1.3 million lower in
1997 than in 1996 on a comparable currency basis. Lower unit sales of FBS
decreased 1997 net sales by $1.8 million while higher unit selling prices
increased net sales by $0.5 million when compared with 1996. The effect of
changes in currency exchange rates reduced 1997 net sales by $12.7 million, or
4%, when compared with 1996.
9
<PAGE>
Net sales for 1996 were $309.5 million, an increase of $37.2 million, or 14%,
over 1995. Sales of products other than FBS increased $38.9 million, or 17%,
when comparing 1996 net sales with 1995 and excluding the effect of changes due
to different currency translation rates. FBS sales were $1.5 million higher in
1996 than in 1995 on a comparable currency basis. Higher unit sales of FBS
increased 1996 net sales by $3.2 million while lower unit selling prices
decreased net sales by $1.7 million when compared with 1995. The impact of
consolidating the results of the Company's Japanese subsidiary, effective
September 1, 1995, represented approximately 3% of the 14% increase in net sales
for 1996. The effect of changes in currency exchange rates decreased 1996 net
sales by $3.2 million, or 1%, when compared with 1995.
FBS represented 13% of net sales in 1997, 14% of net sales in 1996 and 16% of
net sales in 1995.
Royalty income was $1.8 million, $0.9 million and $0.1 million in 1997, 1996 and
1995, respectively. Royalty income relates principally to the Company's
patented technology to improve the accuracy of amplification based assays. The
Company generally grants a license to this technology for an up-front fee and
future royalties on sales of products which incorporate the licensed technology.
Royalty income based on licensee sales of products incorporating technology
licensed from the Company was $1.6 million in 1997, $0.4 million in 1996 and
none in 1995.
COST OF SALES - GROSS MARGIN
Gross margins were 53.9% of net sales in 1997 compared with 52.5% of net sales
in 1996. FBS gross margins improved in 1997 when compared with 1996,
principally due to lower unit costs in 1997. The Company reduced its LIFO
reserves in the amount of $1.4 million during 1997, largely as a result of lower
unit costs for FBS. Gross margins also benefited from a favorable change in the
mix of sales, production efficiencies and lower scrap costs.
Gross margins were 52.5% of net sales in 1996 compared with 50.1% of net sales
in 1995. Gross margins improved in 1996 as FBS gross margins increased and the
Company realized higher gross margins in Japan. FBS gross margins improved as
FBS unit costs decreased at a faster rate than FBS unit selling prices when
comparing 1996 with 1995. Reported gross margins for Japanese sales were higher
in 1996 principally as a result of consolidating the results of the Company's
Japanese subsidiary upon acquisition of a controlling interest in that
subsidiary in September 1995. The Company reduced its LIFO reserves in the
amount of $3.3 million during 1996, largely as a result of lower unit costs for
FBS.
MARKETING AND ADMINISTRATIVE EXPENSES
Marketing and administrative expenses were 32.6% of net sales in both 1997 and
1996, and 32.0% of net sales in 1995. The increase in marketing and
administrative expenses, expressed as a percentage of sales, over the period
from 1995 through 1997 is primarily attributable to costs related to
implementing the Company's new management information system, to acquiring and
protecting intellectual property rights, and to the consolidation of the
financial results of the Company's Japanese subsidiary beginning September 1995.
RESEARCH AND DEVELOPMENT ("R&D") EXPENSES
Research and development expenses were $21.3 million in 1997, $19.1 million in
1996 and $15.9 million in 1995. R&D expenses in 1997, 1996 and 1995 were
10
<PAGE>
directed primarily toward developing new products and business solutions for the
Company's customers in the life sciences research and industrial bioprocessing
areas and toward improving production processes.
Research and development expenses represented 6.4%, 6.2%, and 5.8% of net sales
in 1997, 1996 and 1995, respectively.
GAIN ON PRODUCT LINE DISPOSAL
The Company reported a $2.6 million gain in 1996 on the disposal of its
molecular diagnostics product line which was sold in 1990 for book value plus a
$2.6 million note receivable. The Company delayed recognition of the gain on
this sale until the note was collected because of reasonable doubt as to whether
the note might be collected. The Company received payments on the note,
primarily for interest, from the time the note was first issued. All interest
payments were included in interest income.
OPERATING INCOME
Operating income for 1997 was $50.9 million, an increase of 10% compared with
1996. The increase in operating income was 17% when comparing 1997 results with
1996 operating income and excluding the one-time gain on the product line
disposal from 1996 results. The percentage increase in adjusted operating
income was greater than the percentage increase in net sales principally due to
the improvement in gross margins. Changes in currency exchange rates used to
translate non-U.S. earnings to U.S. dollars decreased operating income in 1997
by $1.1 million when compared with 1996.
Operating income for 1996 was $46.1 million, an increase of $11.9 million, or
35%, compared with 1995. The gain on a product line disposal represented 8% of
the 35% increase in operating income. Adjusting for this gain, operating income
increased 27% compared with a 14% increase in net sales when comparing 1996 with
1995. The percentage increase in operating income was greater than the
percentage increase in net sales principally due to the improvement in gross
margins. Changes in currency exchange rates used to translate non-U.S. earnings
to U.S. dollars decreased operating income in 1996 by $0.7 million when compared
with 1995.
OTHER INCOME AND EXPENSES
Investment income was $0.5 million in 1997, $0.7 million in 1996, and $0.9
million in 1995. Investment income in 1996 and 1995 included $0.1 million and
$0.2 million, respectively, related to an interest bearing note received upon
the disposition of the Company's molecular diagnostics product line in late
1990.
INCOME TAXES
Income taxes were 36.0% of pre-tax income in both 1997 and 1996, compared with
34.8% in 1995.
MINORITY INTERESTS
Income attributed to minority interest investors was $0.6 million in 1997, $1.2
million in 1996, and $0.5 million in 1995. The decrease in 1997 compared with
1996 is due to lower minority ownership in the Company's Japanese subsidiary in
1997, as well as lower earnings in 1997 at entities less than 100% owned by the
Company. The increase in 1996 compared with 1995 is related to higher earnings
in 1996 at entities less than 100% owned by the Company and
11
<PAGE>
a full year of minority interest adjustments in 1996 compared with four months
of adjustments in 1995 for the Company's Japanese subsidiary which was
consolidated in the Company's financial statements effective September 1, 1995.
NET INCOME
Net income was $32.2 million in 1997, $28.7 million in 1996, and $22.3 million
in 1995. Excluding the one-time gain on the product line disposal from 1996
results, net income has increased 19%, 21%, and 22% in 1997, 1996, and 1995,
respectively.
EARNINGS PER SHARE
The Company has reported its per share earnings in accordance with Statement of
Financial Accounting Standards No. 128, Earnings per Share ("SFAS No. 128").
This new accounting standard applies to all companies with publicly traded
common stock or potential common stock and was effective for reporting periods
ending after December 15, 1997. SFAS No. 128 requires the Company to make a
dual presentation of basic and diluted earnings per share on the income
statement. Basic earnings per share is based on shares of common stock actually
outstanding and is compatible with the reporting standards of most other
countries. Diluted earnings per share gives effect to all dilutive potential
common shares outstanding and is consistent with the Company's former
presentation of primary earnings per share under APB Opinion No. 15, the
reporting standard for earnings per share prior to SFAS No. 128. SFAS No. 128
does not address which earnings per share presentation should be discussed in
reviews of financial results. The Company has elected to discuss diluted
earnings per share in this initial period of adoption for SFAS No. 128. The
Company will monitor industry practice in this area and will likely focus in the
future on the presentation that becomes the industry standard.
Diluted earnings per share were $1.35 in 1997, which constituted an increase of
11% when compared with diluted earnings per share of $1.22 in 1996. Excluding
the one-time gain reported in 1996 related to the disposition of a product line,
diluted earnings per share increased 17%.
Diluted earnings per share were $1.22 in 1996, and represented a 26% increase
when compared with diluted earnings per share of $0.97 in 1995. Excluding the
one-time gain reported in 1996 related to the disposition of a product line,
diluted earnings per share increased 19%.
BUSINESS OUTLOOK
The Company expects to concentrate on its core cell and molecular biology and
cell culture product lines and related service offerings in 1998. Future trends
in the Company's markets may be affected by government funding for life sciences
research, the number of new products developed and introduced by the Company's
customers, and changes in technology and scientific discoveries.
Changes in currency exchange rates, economic and currency instability,
especially in Asia, the supply and price of FBS, and the availability of well-
trained employees throughout the world are factors that could have a significant
effect on the Company in 1998. The current strength of the U.S. dollar and Pound
Sterling against other currencies, especially European and Japanese currencies,
could have a negative effect on the Company's results.
Volatility in the FBS market will continue to significantly affect the Company's
results. The market volatility of FBS and the increasing demand for
12
<PAGE>
alternative media provide strong incentive to develop products and technologies
which are not dependent on animal sera raw materials. To date, serum-free media
has only been developed for specific, relatively narrow purposes. If a more
broadly applicable alternative to animal derived products were developed, it
could have a significant effect on the Company's results, which could be
positive or negative, depending on what rights were held by the Company in the
alternative products.
Heightened worldwide safety and environmental concerns are likely to lead to
increased regulation in these areas. The Company is committed to promoting the
safety and health of its employees and the environment and will remain pro-
active in complying with federal, state and local regulations.
The Company is in the process of replacing its core financial, order
entry/distribution, and manufacturing systems at its major locations worldwide.
The Company has been advised by the software vendor that the release/version of
the software being implemented by the Company is Year 2000 compliant. The
Company is also conducting a review of other internal and external systems which
may require modification or upgrade to be made Year 2000 compliant. The Company
is in the process of working with its customers and suppliers to identify,
modify or upgrade its existing systems which are not currently Year 2000
compliant. The Company believes that the cost of completing the modifications
necessary to become Year 2000 compliant will not be material. There can be no
assurance, however, that the Company will be able to identify all aspects of its
business that are subject to Year 2000 problems, or identify Year 2000 problems
of customers or suppliers that affect the Company's business. There also can be
no assurance that the Company's software vendors are correct in their assertions
that the software is Year 2000 compliant or that the Company's estimate of the
cost of systems preparation for Year 2000 compliance will prove ultimately to be
accurate.
LIQUIDITY AND CAPITAL RESOURCES
1997 CASH FLOWS
The Company generated $31.6 million in cash from operations during 1997. Net
income after adjustments for depreciation and amortization was the principal
source of cash from operations in 1997. The components of working capital
increased at a rate generally commensurate with the increase in net sales and,
in the aggregate, required $14.1 million in cash during 1997.
The Company paid $27.3 million in cash for capital expenditures in 1997. Capital
spending in 1997 included $11.4 million for the Company's new corporate R&D
center in Maryland, $7.2 million for the adjoining corporate administration
building, and $3.0 million for other facilities expansion and modernization
programs. The balance of 1997 capital spending was for new and replacement
machinery and equipment and management information systems related to the
Company's ongoing business operations. The Company paid $0.7 million in deferred
purchase payments related to the 1996 acquisition of Custom Primers, Inc., a
California-based producer of oligonucleotides and $0.2 million in deferred
purchase payments related to the 1994 acquisition of a distributor in Sweden.
Financing activities provided $1.3 million in cash to the Company during 1997.
The Company received $4.1 million in cash during 1997 related to the exercise of
stock options. An additional $1.9 million was provided from short-term
borrowings. The Company used $3.9 million for its quarterly cash dividends and
$0.7 million to reduce long-term debt in 1997.
13
<PAGE>
1998 CASH FLOWS
Capital expenditures in 1998 are expected to range from $20-25 million. The
Company is contemplating additional facility upgrades and expansions of $5-15
million with the balance of expected 1998 capital expenditures for new and
replacement machinery, equipment and management information systems.
The Company is actively evaluating licensing possibilities, as well as
acquisition candidates which complement the Company's core cell and molecular
biology and cell culture product lines. The Company may fund these transactions
using cash from operations, debt, equity, or other sources.
The Board of Directors intends to consider the declaration and payment of
quarterly dividends in the future based on the operating performance of the
Company. In addition, the Board of Directors has recommended to the
stockholders of the Company a proposal to authorize management to repurchase up
to one million shares of the common stock of the Company over a 24 month period
for cash, in the open market or in privately negotiated transactions.
The Company currently has an unused short-term revolving credit facility with
The Dexter Corporation, an affiliate of the Company, in the amount of $8.0
million.
The Company believes it will be able to generate sufficient cash from its
operations and its existing credit facility to meet all its anticipated cash
requirements in 1998 apart from any significant business acquisition which may
occur and which may be financed using cash from operations, debt, equity, or
other sources.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
- -------- ----------------------------------------------------------
Not applicable.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
- ------- -------------------------------------------
The Financial Statements and Supplementary Data appear on pages F-1 through F-21
of this 1997 Annual Report on Form 10-K.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
- ------- ---------------------------------------------------------------
FINANCIAL DISCLOSURE
--------------------
None.
PART III
--------
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
- -------- --------------------------------------------------
Information regarding directors of the Company and compliance by the directors
and officers of the Company with certain reporting requirements pursuant to
Section 16(a) of the Securities Exchange Act of 1934 is contained under the
caption "Proposal No. 1 - Election of Directors" in the Company's Proxy
Statement, which is incorporated herein by reference. Information regarding
executive officers of the Company is included in Part I hereof, under the
caption "Executive Officers of the Registrant."
14
<PAGE>
ITEM 11. EXECUTIVE COMPENSATION
- -------- ----------------------
The information required by this item is contained under the captions "Executive
Compensation" and "Compensation of Directors" in the Company's Proxy Statement,
which is incorporated herein by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
- -------- --------------------------------------------------------------
The information required by this item is contained under the caption "Beneficial
Ownership of Common Stock" in the Company's Proxy Statement, which is
incorporated herein by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
- -------- ----------------------------------------------
None.
PART IV
-------
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
- -------- ----------------------------------------------------------------
(a) (1) Financial Statements:
a. Report of Independent Accountants
b. Consolidated Statement of Income for the
years ended December 31, 1997, 1996 and 1995
c. Consolidated Balance Sheet as of December 31,
1997 and 1996
d. Consolidated Statement of Cash Flows for the
years ended December 31, 1997, 1996 and 1995
e. Consolidated Statement of Changes in
Stockholders' Equity for the years ended
December 31, 1997, 1996 and 1995
f. Notes to Consolidated Financial Statements
(a) (2) Financial Statement Schedules:
None.
All schedules have been omitted because they are not required, not
applicable, or the information required to be set forth therein is
included in the Company's consolidated financial statements.
(a) (3) Exhibits:
Exhibit numbers 10(A),(B),(C),(D),(E),(F),(G),(H),(I),(J),(K),(L)
(M),(N) and (O) are management contracts, compensatory plans or
arrangements.
3(A) Certificate of Incorporation of the Registrant including
Amendment to Certificate of Incorporation dated April 17, 1987,
previously filed as Exhibit 3(A) to the Registrant's Annual
Report on Form 10-K for the year ended December 31, 1992, which
is incorporated herein by reference.
15
<PAGE>
3(B) By-laws of the Registrant as amended and restated on April 16,
1991, previously filed as Exhibit 3(B) to the Registrant's Annual
Report on Form 10-K for the year ended December 31, 1991, which
is incorporated herein by reference.
4(A) Instruments defining the rights of security holders, including
indentures.
Registrant by this filing agrees, upon request, to file with the
Securities and Exchange Commission the instruments defining the
rights of holders of its long-term debt where the total amount of
securities authorized thereunder does not exceed 10% of the total
assets of registrant and its subsidiaries on a consolidated
basis.
10(A) 1984 Stock Option Plan, previously filed as Exhibit 4.1 to the
Registrant's Registration Statement on Form S-8, No. 33-21807,
dated May 12, 1988, which is incorporated herein by reference.
10(B) Executive Supplemental Retirement Plan, previously filed as
Exhibit 10(B) to the Registrant's Annual Report on Form 10-K for
the year ended December 31, 1990, SEC file no. 0-14991, which is
incorporated herein by reference.
10(C) Executive Deferred Compensation Benefit Plan, previously filed
as Exhibit 10.8 to the Registrant's Registration Statement on
Form S-1, No. 33-7993, dated October 1, 1986, which is
incorporated herein by reference.
10(D) Change-in-Control Agreement dated February 13, 1997, between
the Registrant and Dr. J. Stark Thompson regarding certain
severance benefits in the event of termination of employment
following a change of control, as defined in the agreement,
previously filed as Exhibit 10.2 to the Registrant's Quarterly
Report on Form 10-Q for the quarter ended March 31, 1997, SEC
file no. 0-14991, which is incorporated herein by reference.
10(E) Change-in-Control Agreement dated February 13, 1997, between
the Registrant and Joseph C. Stokes, Jr. regarding certain
severance benefits in the event of termination of employment
following a change of control, as defined in the agreement,
previously filed as Exhibit 10.3 to the Registrant's Quarterly
Report on Form 10-Q for the quarter ended March 31, 1997, SEC
file no. 0-14991, which is incorporated herein by reference.
10(F) Change-in-Control Agreement dated February 13, 1997, between
the Registrant and Thomas M. Coutts regarding certain severance
benefits in the event of termination of employment following a
change of control, as defined in the agreement, previously filed
as Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended March 31, 1997, SEC file no. 0-14991, which
is incorporated herein by reference.
16
<PAGE>
10(G) Change-in-Control Agreement dated February 13, 1997, between
the Registrant and John V. Cooper regarding certain severance
benefits in the event of termination of employment following a
change of control, as defined in the agreement, previously filed
as Exhibit 10.5 to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended March 31, 1997, SEC file no. 0-14991, which
is incorporated herein by reference.
10(H) Executive Deferred Compensation Benefit Plan, previously filed
as Exhibit 10(H) to the Registrant's Annual Report on Form 10-K
for the year ended December 31, 1991, SEC file no. 0-14991, which
is incorporated herein by reference.
10(I) 1991 Stock Option Plan, previously filed as Exhibit 4 to the
Registrant's Registration Statement on Form S-8 No. 33-956, dated
May 9, 1991, which is incorporated herein by reference.
10(J) 1995 Long-term Incentive Plan, previously filed as Exhibit 4 to
the Registrant's Registration Statement on Form S-8 No. 33-59741,
dated June 1, 1995, which is incorporated herein by reference.
10(K) Change-in-Control Agreement dated February 13, 1997, between
the Registrant and John E. Leffler regarding certain severance
benefits in the event of termination of employment following a
change of control, as defined in the agreement, previously filed
as Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended March 31, 1997, SEC file no. 0-14991, which
is incorporated herein by reference.
10(L) 1996 Non-Employee Directors' Stock Option Plan, previously
filed as Exhibit 4(b) to the Registrant's Registration
Statement on Form S-8 No. 333-03773, dated May 15, 1996, which is
incorporated herein by reference.
10(M) 1996 Non-Employee Directors' Annual Retainer Stock Plan,
previously filed as Exhibit 4(a) to the Registrant's
Registration Statement on Form S-8 No. 333-03773, dated May 15,
1996, which is incorporated herein by reference.
10(N) Form of Employment Agreement effective February 13, 1997,
between the Registrant and certain executive officers of the
Registrant regarding certain severance benefits in the event of
termination of employment following a change in control, as
defined in the agreement, previously filed as Exhibit 10.6 to the
Registrant's Quarterly Report on Form 10-Q for the quarter ended
March 31, 1997, SEC file no. 0-14991, which is incorporated
herein by reference.
10(O) 1997 Long-term Incentive Plan, previously filed as Exhibit 4 to
the Registrant's Registration Statement on Form S-8 No. 333-
28607, dated June 6, 1997, which is incorporated herein by
reference.
17
<PAGE>
21 Subsidiaries of the Registrant.
23 Consent of Independent Accountants.
27 Financial Data Schedule.
Exhibits other than those incorporated herein by reference have been
included in copies of this Form 10-K filed with the Securities and
Exchange Commission. The Registrant agrees that it will furnish,
without charge, a copy of any such exhibits to each stockholder of the
Registrant upon the written request therefore to the Registrant.
(b) Reports on Form 8-K.
None.
(c) Exhibits
See (a) (3) above.
(d) Financial Statement Schedules
See (a) (2) above.
18
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
Dated February 27, 1998 LIFE TECHNOLOGIES, INC.
(Registrant)
By /s/ Joseph C. Stokes, Jr.
----------------------------------------
Joseph C. Stokes, Jr.
Senior Vice President and
Chief Financial Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed below by the following persons on behalf of the Registrant and
in the capacities indicated.
/s/ Thomas H. Adams, Ph.D. /s/ J. Stark Thompson, Ph.D.
- -------------------------- ----------------------------
Thomas H. Adams, Ph.D. J. Stark Thompson, Ph.D.
Director President and Chief Executive Officer
and Director
(Principal Executive Officer)
/s/ Bruce H. Beatt /s/ K. Grahame Walker
- ------------------ ---------------------
Bruce H. Beatt K. Grahame Walker
Director Chairman of the Board of Directors
/s/ Kathleen Burdett /s/ Iain C. Wylie
- -------------------- -----------------
Kathleen Burdett Iain C. Wylie
Director Director
/s/ Betsy Z. Cohen /s/ Joseph C. Stokes, Jr.
- ------------------ -------------------------
Betsy Z. Cohen Joseph C. Stokes, Jr.
Director Senior Vice President and
Chief Financial Officer
(Principal Financial Officer)
/s/ Rita R. Colwell, Ph.D. /s/ C. Eric Winzer
- -------------------------- ------------------
Rita R. Colwell, Ph.D. C. Eric Winzer
Director Controller
(Principal Accounting Officer)
/s/ Frank E. Samuel, Jr.
- ------------------------
Frank E. Samuel
Director
19
<PAGE>
INDEX TO FINANCIAL STATEMENTS AND SCHEDULES
Financial Statements: Page
Index to Financial Statements and Schedules F-1
Report of Independent Accountants F-2
Consolidated Statement of Income for the
years ended December 31, 1997, 1996 and 1995 F-3
Consolidated Balance Sheet as of December 31,
1997 and 1996 F-4
Consolidated Statement of Cash Flows for the
years ended December 31, 1997, 1996 and 1995 F-5
Consolidated Statement of Changes in F-6
Stockholders' Equity for the years ended
December 31, 1997, 1996 and 1995
Notes to Consolidated Financial Statements F-7
Financial Statement Schedules:
None.
All schedules have been omitted because they are not
required, not applicable, or the information required to
be set forth therein is included in the Company's
consolidated financial statements.
F-1
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Stockholders and Board of Directors of
Life Technologies, Inc.
We have audited the consolidated financial statements of Life Technologies, Inc.
and its subsidiaries listed in Item 14(a)(1) of this Form 10-K. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the consolidated financial position of Life Technologies,
Inc. and its subsidiaries as of December 31, 1997 and 1996, and the consolidated
results of their operations and their cash flows for each of the three years in
the period ended December 31, 1997 in conformity with generally accepted
accounting principles.
/s/ Coopers & Lybrand L.L.P.
----------------------------
Coopers & Lybrand L.L.P.
McLean, Virginia
January 23, 1998
F-2
<PAGE>
Life Technologies, Inc.
Consolidated Statement of Income
(amounts in thousands, except per share data)
<TABLE>
<CAPTION>
For the years ended December 31, 1997 1996 1995
========= ========== =========
<S> <C> <C> <C>
Revenues:
Net sales $330,967 $309,455 $272,232
Net royalties 1,841 884 67
-------- -------- --------
Total revenues 332,808 310,339 272,299
-------- -------- --------
Expenses:
Cost of sales 152,547 146,926 135,213
Marketing and administrative 108,046 100,797 87,063
Research and development 21,281 19,084 15,871
Gain on product line disposal - (2,569) -
-------- -------- --------
Total expenses 281,874 264,238 238,147
-------- -------- --------
Operating income 50,934 46,101 34,152
-------- -------- --------
Other income (expense):
Investment income 474 708 867
Interest expense (70) (89) (76)
-------- -------- --------
Total other income 404 619 791
-------- -------- --------
Income before income taxes 51,338 46,720 34,943
Income taxes 18,481 16,819 12,160
-------- -------- --------
Income before minority interests 32,857 29,901 22,783
Minority interests (622) (1,201) (506)
-------- -------- --------
Net income $ 32,235 $ 28,700 $ 22,277
======== ======== ========
Earnings per share:
Basic $1.39 $1.25 $.99
Diluted $1.35 $1.22 $.97
Average shares outstanding:
Basic 23,171 22,881 22,601
Diluted 23,945 23,504 22,929
Cash dividends declared per share $.18 $.15 1/3 $.13 1/3
======== ======== ========
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
F-3
<PAGE>
Life Technologies, Inc.
Consolidated Balance Sheet
(amounts in thousands, except share data)
<TABLE>
<CAPTION>
December 31, 1997 1996
========= =========
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 19,076 $ 15,326
Accounts receivable, net 58,096 54,566
Inventories:
FIFO 69,696 65,312
LIFO reserve (1,633) (2,992)
-------- --------
Total inventory 68,063 62,320
Prepaid expenses 4,485 3,109
Current deferred tax assets 5,738 5,176
-------- --------
Total current assets 155,458 140,497
Property, plant and equipment, net 100,098 88,367
Other assets 12,353 11,023
Excess of cost over net assets of businesses
acquired, net 12,365 14,044
-------- --------
Total assets $280,274 $253,931
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Short-term debt $ 2,976 $ 2,004
Accounts payable 21,420 20,976
Accrued and deferred income taxes 7,237 11,256
Accrued liabilities and expenses 22,898 22,065
-------- --------
Total current liabilities 54,531 56,301
Long-term debt 4,564 4,668
Pension liabilities 5,768 4,471
Deferred income taxes 3,695 3,165
Minority interests 2,992 2,407
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, one million
shares authorized; none issued
Common stock, $.01 par value, 50 million
shares authorized; issued and outstanding
23,350,979 in 1997 and
22,951,313 in 1996 234 230
Additional paid-in capital 54,503 48,344
Retained earnings 161,689 133,633
Currency exchange effects (7,702) 712
-------- --------
Total stockholders' equity 208,724 182,919
-------- --------
Total liabilities and stockholders' equity $280,274 $253,931
======== ========
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
F-4
<PAGE>
Life Technologies, Inc.
Consolidated Statement of Cash Flows
(amounts in thousands)
<TABLE>
<CAPTION>
For the years ended December 31, 1997 1996 1995
========= ========= =========
<S> <C> <C> <C>
CASH INFLOWS (OUTFLOWS)
Operations:
Net income $ 32,235 $ 28,700 $ 22,277
Non-cash items:
Depreciation 10,126 8,293 7,136
Amortization 2,591 2,283 592
Deferred income taxes (627) (533) (419)
Gain on product line disposal - (2,569) -
Minority interests in net income 622 1,201 506
Changes in assets and liabilities
net of acquisitions:
Accounts receivable (7,232) (6,898) (5,892)
Inventories (9,035) 140 (4,435)
Prepaid expenses (1,591) 472 (1,355)
Accounts payable 3,286 3,448 (707)
Accrued income taxes (1,783) (1,764) 1,307
Accrued liabilities and expenses 2,299 6,661 1,818
Other 719 830 523
-------- -------- --------
Cash provided by operating activities 31,610 40,264 21,351
-------- -------- --------
Investments:
Capital expenditures (27,300) (36,017) (12,279)
Acquisitions and joint ventures (914) (11,704) (825)
Proceeds from product line disposal - 2,569 -
Other (127) (30) (28)
-------- -------- --------
Cash used in investing activities (28,341) (45,182) (13,132)
-------- -------- --------
Financing:
Dividends paid (3,929) (3,351) (3,007)
Proceeds from exercise of stock options 4,052 1,998 2,990
Short-term borrowings, net 1,896 319 -
Long-term loan repayments (713) (1,617) -
-------- -------- --------
Cash provided by (used in)
financing activities 1,306 (2,651) (17)
-------- -------- --------
Effect of exchange rate changes on cash (825) (306) (381)
-------- -------- --------
Increase (decrease) in cash and
cash equivalents 3,750 (7,875) 7,821
Cash included from consolidation of a
subsidiary which became majority owned
in 1995 - - 2,134
Cash and cash equivalents at beginning
of year 15,326 23,201 13,246
-------- -------- --------
Cash and cash equivalents at end of year $ 19,076 $ 15,326 $ 23,201
======== ======== ========
Supplemental cash flow information:
Cash paid during the year:
Income tax, net of refunds $ 20,081 $ 18,092 $ 11,354
Non-cash financing activity:
Capital lease - $ 4,739 -
======== ======== ========
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
F-5
<PAGE>
Life Technologies, Inc.
Consolidated Statement of Changes in Stockholders' Equity
(amounts in thousands)
<TABLE>
<CAPTION>
Additional Currency
Common Stock Paid-in Retained Exchange
Shares Amount Capital Earnings Effects Total
------------ -------- -------- -------- ------- --------
<S> <C> <C> <C> <C> <C> <C>
Balances at
December 31, 1994 22,471 $ 150 $42,561 $ 89,184 $(1,766) $130,129
Net income 22,277 22,277
Dividends-$.13-1/3 per share (3,017) (3,017)
Shares issued under
stock option plans 302 2 2,988 2,990
Tax benefit on stock
option plans 446 446
Currency effects 1,100 1,100
------------ -------- -------- -------- ------- --------
Balances at
December 31, 1995 22,773 152 45,995 108,444 (666) 153,925
Net income 28,700 28,700
Dividends-$.15-1/3 per share (3,511) (3,511)
Shares issued under
stock option and stock
grant plans 178 2 1,996 1,998
Tax benefit on stock
option plans 429 429
Stock split 76 (76) -
Currency effects 1,378 1,378
------------ -------- -------- -------- ------- --------
Balances at
December 31, 1996 22,951 230 48,344 133,633 712 182,919
Net income 32,235 32,235
Dividends-$.18 per share (4,179) (4,179)
Shares issued under
stock option and stock
grant plans 400 4 4,124 4,128
Tax benefit on stock
option plans 2,035 2,035
Currency effects (8,414) (8,414)
------------ -------- -------- -------- ------- --------
Balances at
December 31, 1997 23,351 $ 234 $54,503 $161,689 $(7,702) $208,724
============ ====== ======== ======== ======= ========
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
F-6
<PAGE>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
=============================================================================
BASIS OF CONSOLIDATION AND PRESENTATION
The consolidated financial statements include the accounts of Life Technologies,
Inc. (the "Company" or "Life Technologies") and its majority owned or controlled
subsidiaries. Intercompany accounts, transactions, and profits have been
eliminated in the consolidated financial statements. Investments in affiliated
companies (20% to 50% Life Technologies' ownership) are recorded in the
consolidated financial statements using the equity method of accounting except
in cases where the Company can effectively exercise control. In these cases,
the accounts of the affiliate are included in the Company's consolidated
financial statements. Certain amounts for prior years have been reclassified to
conform to, and be consistent with, the 1997 presentation.
Management has made estimates and assumptions in the preparation of these
financial statements that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
NATURE OF OPERATIONS
Life Technologies is a multinational firm that develops, manufactures, and sells
cell and molecular biology products and cell culture products used principally
in life sciences research and commercial manufacture of genetically engineered
products. The Company's principal customers consist of laboratories generally
associated with universities, medical research centers, and government
institutions as well as biotechnology, pharmaceutical, energy, agricultural and
chemical companies. The Company is engaged in one line of business.
Sales of fetal bovine serum ("FBS") accounted for 13% of net sales in 1997, 14%
in 1996 and 16% in 1995. Historically, the availability and price of FBS have
been volatile and periodically have had a significant effect on the Company's
results.
BUSINESS ACQUISITIONS
In January 1996, the Company paid $7.1 million to purchase 75% of the common
stock of Custom Primers, Inc. ("CPI"), a California-based producer of
oligonucleotides, increasing the Company's ownership to 100%. The Company had
acquired 25% of CPI in several transactions prior to 1996 valued at $0.8
million. Based upon the net assets purchased in January 1996 and the total cash
paid of $7.9 million, the Company recorded $7.4 million in excess of net assets
acquired ("goodwill") in 1996. The January 1996 purchase agreement provides for
additional earn-out contingencies based on the sales of oligonucleotides over
the five year period following the date of the purchase agreement. For the
years 1997 and 1996, the Company recorded additional earn-outs of $1.0 and $0.8
million, respectively. The original intangible is being amortized over five
years and additional intangibles resulting from earn-outs are being amortized
over the remaining term of the original amortization period.
In September 1996, the Company acquired an additional 29% ownership of its
Japanese subsidiary, Life Technologies Oriental, K.K. ("LTOKK"), for $3.7
million. This additional purchase increased the Company's ownership from 51%
F-7
<PAGE>
to 80% and resulted in $1.8 million of additional goodwill. In September 1995,
the Company increased its ownership of LTOKK from 50% to 51% at a cost of
$150,000, which approximated book value. This additional ownership resulted in
the consolidation of LTOKK's financial results as of September 1995. Prior to
September 1995, the Company accounted for LTOKK using the equity method of
accounting. Equity income reported for LTOKK was $0.5 million for the first
eight months of 1995 and is included as an adjustment to cost of sales for that
year. Sales for LTOKK, which were not included in the Company's financial
statements prior to consolidation, were $22.2 million in the first eight months
of 1995.
None of the businesses acquired during the period, individually or in the
aggregate, constitute a significant subsidiary of the Company.
TECHNOLOGY AGREEMENTS
The Company has obtained rights to products and technologies under a number of
licensing agreements or patents. Where the agreement requires the Company to
pay royalties on sales of licensed products or technologies, the Company
includes the royalty expense in cost of sales in the period of the sale. Where
the Company acquires technologies from outside sources for incorporation into
its own development efforts or products, the cost of the technology is
capitalized and amortized over the legal or expected useful life when the
technology is currently commercially applicable. Where considerable development
effort is required to have acquired technologies become part of the Company's
product lines, the cost of the acquired technologies is reported as research and
development expense in the period the technology is acquired. Internal efforts
to develop or patent technologies are expensed when incurred.
The Company also licenses technology it has developed to others. The Company
recognizes revenue on these licenses when payment is reasonably certain.
Revenues are reduced by related transaction expenses.
EARNINGS PER SHARE
In 1997, the Company adopted SFAS No. 128, Earnings Per Share. Basic earnings
per common share have been computed by dividing net income by the weighted-
average number of common shares outstanding during the period. Diluted earnings
per common share have been computed by dividing net income by the weighted-
average number of common shares outstanding plus an assumed increase in common
shares outstanding for dilutive securities. Net income as reported is available
to common stockholders and is not adjusted for basic or diluted earnings per
share. Dilutive securities consist entirely of options to acquire common stock
for a specified price and their dilutive effect is measured using the treasury
method. Earnings per share for all other periods presented have been restated
to conform to SFAS No. 128.
The following table reconciles the weighted average number of common shares
outstanding during each period for basic earnings per share with the comparable
amount for diluted earnings per share.
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996 1995
====== ====== ======
<S> <C> <C> <C>
Weighted average shares outstanding-basic 23,171 22,881 22,601
Stock options 774 623 328
------ ------ ------
Weighted average shares outstanding-diluted 23,945 23,504 22,929
====== ====== ======
</TABLE>
F-8
<PAGE>
RELATED PARTY - DEXTER
At December 31, 1997, The Dexter Corporation ("Dexter") owned approximately 52%
of the outstanding shares of the Company's common stock. Most transactions with
Dexter are administrative in nature (e.g., insurance) and are not significant in
amount. The Company has no significant product sales to Dexter or its
affiliates. Three executives of Dexter served as directors of the Company in
1997. Two executives of Dexter served as directors of the Company in 1996 and
1995.
The Company can borrow up to $8.0 million under a revolving line of credit from
Dexter to finance short-term working capital needs. There have been no amounts
outstanding under this line of credit since prior to 1995.
NEW ACCOUNTING STANDARDS
The Financial Accounting Standards Board has issued two new standards which
become effective for reporting periods beginning after December 15, 1997. SFAS
No. 130, Reporting Comprehensive Income, requires additional disclosures with
respect to certain changes in assets and liabilities that previously were not
required to be reported as results of operations for the period. The Company
will begin making the additional disclosures required by SFAS No. 130 in the
first quarter of 1998. SFAS No. 131, Disclosures about Segments of an
Enterprise and Related Information, requires financial and descriptive
information with respect to "operating segments" of an entity based on the way
management disaggregates the entity for making internal operating decisions. The
Company will begin making the disclosures required by SFAS No. 131 with
financial statements for the period ending December 31, 1998.
CASH AND CASH EQUIVALENTS
Cash equivalents are highly liquid short-term investments readily convertible
into cash. Cash equivalents consist primarily of time deposits and certificates
of deposit with various financial institutions throughout the world. These
investments are carried at cost, which approximates market, and mature within 90
days and, therefore, are subject to minimal risk.
ACCOUNTS RECEIVABLE
Accounts receivable are reduced by allowances of $1.6 million and $1.5 million
at December 31, 1997 and 1996, respectively.
INVENTORIES
Inventories are valued at the lower of cost or market. Inventories valued at
cost using the LIFO method were approximately 30% of total inventories at both
December 31, 1997 and 1996. Inventories were as follows:
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996
======== ========
<S> <C> <C>
Materials and supplies $12,082 $11,844
Work-in-process 9,906 10,241
Finished goods 47,708 43,227
------- -------
Total FIFO value 69,696 65,312
LIFO reserve (1,633) (2,992)
------- -------
Total inventory $68,063 $62,320
======= =======
</TABLE>
F-9
<PAGE>
PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are carried at cost. Depreciation is provided by
the straight-line method for financial reporting purposes based upon the
estimated useful lives of the assets which range from 3 to 50 years. The cost
of assets sold or retired and the related amounts of accumulated depreciation
are eliminated from the accounts and the resulting gain or loss is included in
income. Renewals and betterments are capitalized. Repairs and maintenance are
charged to expense when incurred and were $4.5 million in 1997, $3.4 million in
1996, and $2.7 million in 1995.
Interest is capitalized in connection with the construction of major facilities.
Capitalized interest is recorded as part of the cost of the asset to which it
relates and is amortized over the asset's estimated useful life. The Company
capitalized $0.3 million of interest cost in 1997, all of which interest related
to the debt associated with a capital lease. No interest was capitalized in
1996 or 1995.
The cost and accumulated depreciation of property, plant and equipment were as
follows:
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996
========= =========
<S> <C> <C>
Land and land improvements $ 6,184 $ 3,360
Land under a capital lease 4,739 4,739
Buildings and leasehold improvements 63,545 36,756
Machinery and equipment 66,535 57,724
Construction-in-progress 10,365 31,724
-------- --------
Total cost 151,368 134,303
Accumulated depreciation (51,270) (45,936)
-------- --------
Property, plant and equipment, net $100,098 $ 88,367
======== ========
</TABLE>
LEASES
The Company leases buildings, automobiles and equipment under operating lease
arrangements. These leases contain various renewal options, purchase options
and escalation clauses. The total rental expense of all operating leases was
$6.3 million in 1997, $5.8 million in 1996, and $5.9 million in 1995. The
Company has one capital lease which is for a parcel of land on which the Company
is constructing a new corporate R&D center and other administrative offices,
including the Company's headquarters.
The future minimum rental payments required under noncancellable leases as of
December 31, 1997 were as follows:
<TABLE>
<CAPTION>
(amounts in thousands) Capital Lease Operating Leases
============== ================
<S> <C> <C>
For the years ending
1998 $ 440 $ 4,977
1999 440 3,183
2000 440 2,125
2001 440 1,063
2002 440 787
2003 and thereafter 7,085 1,914
------- -------
Total minimum lease payments 9,285 $14,049
Less amount representing interest (4,627)
------- -------
Present value of net minimum lease payments $ 4,658
======= =======
</TABLE>
F-10
<PAGE>
OTHER ASSETS
Significant components of other assets were as follows:
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996
======= =======
<S> <C> <C>
Pension and retirement related $ 4,683 $ 4,264
Software, net of amortization 3,594 3,315
Deferred tax assets 2,775 2,165
Other 1,301 1,279
------- -------
Other assets $12,353 $11,023
======= =======
</TABLE>
EXCESS ACQUISITION COSTS
The excess of costs over the net asset values of businesses acquired prior to
1992 are being amortized on a straight-line basis principally over 30 years.
The excess of costs over net asset values of businesses acquired since 1992 are
being amortized on a straight-line basis over no more than 10 years. The
Company assesses the recoverability of net cost in excess of net assets of
acquired businesses by determining whether the amortization of this intangible
asset over its remaining life can be recovered through future operating cash
flows. The Company makes a specific provision against the asset when impairment
is identified. The Company did not make an impairment charge in 1997, 1996 or
1995. Future acquisitions will be evaluated using this method and an appropriate
useful life will be determined for amortization of the excess of costs over the
net asset value of businesses acquired, if any.
Accumulated amortization at December 31, 1997 and 1996 amounted to $7.9 million
and $5.5 million, respectively.
ACCRUED LIABILITIES AND EXPENSES
Accrued liabilities and expenses were as follows:
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996
======= =======
<S> <C> <C>
Salaries, wages and benefits $ 9,928 $ 9,831
Royalties 3,179 2,570
Deferred purchase and construction payments 1,538 2,745
Other 8,253 6,919
------- -------
Accrued liabilities and expenses $22,898 $22,065
======= =======
</TABLE>
F-11
<PAGE>
DEBT
The following is a summary of the outstanding debt at December 31, 1997 and
1996.
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996
======= =======
<S> <C> <C>
Short-term debt:
Japanese Yen bank borrowings $2,882 $1,286
Current portion of obligations under a capital lease 94 71
Current portion of long-term notes - 647
------ ------
Short-term debt $2,976 $2,004
====== ======
Long-term debt:
Capital lease (7.5%) $4,658 $4,739
Long-term notes
Note due 1997 - 647
------ ------
4,658 5,386
------ ------
Less: Current portion of long-term debt 94 718
------ ------
Long-term debt $4,564 $4,668
====== ======
</TABLE>
Short-term debt consisted of notes payable to various banks denominated in
Japanese Yen, the current portion of obligations under a capital lease and the
current portion of long-term notes. The carrying value of short-term borrowings
approximates fair value. The average interest rate on the Japanese Yen bank
borrowings during the year were 1.56% in 1997 and 1.875% in 1996. Year-end
weighted average interest rates were 1.85% in 1997 and 1.875% in 1996.
The Company currently has an unused short-term revolving credit facility with
The Dexter Corporation, an affiliate of the Company, for $8.0 million.
The capital lease is for a parcel of land on which the Company has constructed a
new corporate R&D center and is constructing an administrative office facility,
including the Company's headquarters. Payments commenced effective February
1997, and are based on a 22 year amortization schedule. The agreement includes
a 50 year renewal clause. The Company also has an option to purchase the land.
Long-term notes consists of Yen 75 million at December 31, 1996 in the form of
promissory notes from the Company's majority owned Japanese subsidiary to the
minority shareholder. The year-end interest rate was 3.2% in 1996. The final
payment of this note was made in the fourth quarter of 1997. The weighted
average interest rate was 3.2% in 1997 and 3.0% in 1996. The fair value of the
Company's long-term debt is estimated by management to approximate the carrying
value at December 31, 1997 and 1996.
F-12
<PAGE>
INCOME TAXES
The differences between the U.S. federal statutory tax rate and the Company's
effective tax rate are as follows:
<TABLE>
<CAPTION>
1997 1996 1995
======== ======== ========
<S> <C> <C> <C>
Statutory U.S. federal income tax rate 35.0% 35.0% 35.0%
State income taxes 1.7 1.5 0.7
Non-U.S. tax rate differences 0.8 1.1 0.7
Repatriation of foreign earnings,
net of related benefits (0.7) (3.3) -
Non-deductible expenses 1.5 1.7 0.4
Other, including tax credits (2.3) - (2.0)
------- ------- -------
Effective income tax rate 36.0% 36.0% 34.8%
======= ======= =======
</TABLE>
The provision (benefit) for taxes on income for 1997, 1996 and 1995 is
summarized below:
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996 1995
======= ======= =======
<S> <C> <C> <C>
Current
United States $ 9,540 $ 7,348 $ 2,759
International 8,569 8,788 9,396
State 999 1,216 424
------- ------- -------
Total current 19,108 17,352 12,579
------- ------- -------
Deferred
United States (497) (838) (532)
International (46) 545 209
State (84) (240) (96)
------- ------- -------
Total deferred (627) (533) (419)
------- ------- -------
Total provision for income taxes $18,481 $16,819 $12,160
======= ======= =======
</TABLE>
Deferred tax assets and liabilities were comprised of the following:
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996
======= =======
<S> <C> <C>
Deferred tax assets:
Intercompany profits $ 2,281 $ 2,164
Retirement benefits 2,211 1,691
Expenses not currently deductible 2,075 1,546
Inventory reserves 1,170 1,144
Other 776 796
------- -------
Gross deferred tax assets 8,513 7,341
------- -------
Deferred tax liabilities:
Fixed assets, principally depreciation 3,182 2,615
Inventory 523 484
Retirement benefits 507 554
Other 85 96
------- -------
Gross deferred tax liabilities 4,297 3,749
------- -------
Net deferred tax asset $ 4,216 $ 3,592
======= =======
</TABLE>
F-13
<PAGE>
Management has determined that tax benefits associated with the net deferred tax
asset will more likely than not be realized based on the availability of taxable
income in prior carryback years against which future tax deductions may be
offset and on expectations that future operating income of the Company will also
be sufficient to realize fully these net deferred tax assets.
U.S. and international withholding taxes have not been provided on approximately
$80.8 million of undistributed earnings of foreign subsidiaries. The Company
remits only those earnings which are considered to be in excess of the
reasonably anticipated working capital needs of the foreign subsidiaries, with
the balance considered to be permanently reinvested in the operations of such
subsidiaries. It is impractical to estimate the total tax liability, if any,
until such a distribution is made. Pretax income from international operations
amounted to $26.6 million in 1997, $30.6 million in 1996, and $28.0 million in
1995.
RETIREMENT BENEFITS
The Company has a qualified pension plan ("defined benefit") and a 401(k) plan
("employee deferral" and "defined contribution") for substantially all United
States employees. With respect to its qualified U.S. pension plan, the Company's
policy is to deposit with an independent trustee amounts as are necessary on an
actuarial basis to provide for benefits in accordance with the requirements of
the Employee Retirement Income Security Act and any other applicable Federal
laws and regulations. The U.S. pension plan provides benefits that are
generally based upon the employee's highest average compensation in any
consecutive five year period in the ten years before retirement. The Company's
401(k) plan allows employees to contribute, on a tax-deferred basis, up to
fifteen percent of their annual base compensation subject to certain regulatory
and plan limitations. The Company matches one half of the employee's 401(k)
deferral up to a maximum of three percent of annual base compensation.
The Company also sponsors an unfunded, nonqualified supplementary retirement
plan for certain senior management. The Company has purchased life insurance on
the lives of participants designed to provide sufficient funds to recover all
costs of the plan. In addition to the above plans, the Company sponsors an
unfunded, nonqualified executive supplemental plan that provides for a target
benefit based upon the average annual compensation during the highest five years
of the last ten years before retirement, which benefit is then offset by other
work related benefits payable to the participant.
The retirement benefits for most employees of non-U.S. operations are generally
provided by government sponsored or insured programs and, in certain countries,
by defined benefit plans. The only significant non-U.S. defined benefit plan is
for United Kingdom employees. The Company's policy with respect to its U.K.
pension plan is to fund amounts as are necessary on an actuarial basis to
provide for benefits under the plan in accordance with local laws and income tax
regulations. The U.K. pension plan provides benefits based upon the employee's
highest average base compensation over three consecutive years.
F-14
<PAGE>
The components of net periodic pension cost and other costs for the retirement
benefits plans during the years 1997, 1996 and 1995 are provided in the
following table.
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996 1995
-------- -------- --------
<S> <C> <C> <C>
Pension Plans:
Service cost $ 2,417 $ 2,188 $ 1,254
Interest cost 2,119 1,757 1,429
Actual return on assets (4,030) (2,877) (2,050)
Net amortization and deferrals 2,604 1,941 974
------- ------- -------
Net periodic pension costs 3,110 3,009 1,607
401(k) employer match program 1,129 998 787
Defined contribution plans and other 580 509 299
------- ------- -------
Total pension costs $ 4,819 $ 4,516 $ 2,693
======= ======= =======
</TABLE>
The assumptions used in accounting for pensions in 1997, 1996 and 1995 were as
follows:
<TABLE>
<CAPTION>
1997 1996 1995
----- ----- -----
<S> <C> <C> <C>
Pension plan assumptions:
Discount rate
Beginning of year:
U.S. 7.00% 6.50% 8.50%
U.K. 8.50% 7.75% 9.75%
End of year:
U.S. 7.00% 7.00% 6.50%
U.K. 7.50% 8.50% 7.75%
Average wage increase:
U.S. 4-5% 4-5% 4-6%
U.K. 6% 6% 6%
Expected long-term rate of
return on plan assets:
U.S. 9% 9% 9%
U.K. 8% 8% 8%
==== ==== ====
</TABLE>
The discount rate is the estimated rate at which the obligation for pension
benefits could effectively be settled. The average wage increase assumption
reflects the Company's best estimate of the future compensation levels of the
individual employees covered by the plans. The expected long-term rate of
return on plan assets reflects the average rate of earnings that the Company
estimates will be generated on the assets of the plans.
F-15
<PAGE>
The funded status of the Company's pension plans and amounts recognized at
December 31, 1997 and 1996 were as follows:
<TABLE>
<CAPTION>
Plans Where Plans Where
Assets Exceed Accumulated Benefits
Accumulated Benefits Exceed Assets
---------------------- ---------------------------
(amounts in thousands) 1997 1996 1997 1996
<S> <C> <C> <C> <C>
Actuarial present value of
benefit obligation:
Vested $21,579 $16,146 $ 1,370 $ 1,221
Accumulated 22,382 16,912 2,034 1,654
Projected 33,176 26,704 2,418 1,894
Plan assets at fair market value 26,940 21,838 - -
------- ------- ------- -------
Projected benefit obligation
in excess of plan assets (6,236) (4,866) (2,418) (1,894)
Unrecognized net loss 2,255 1,474 84 133
Unrecognized prior service cost 2,186 2,492 805 423
Unrecognized net asset (307) (344) - -
Adjustment required to recognize
minimum liability - - (505) (316)
------- ------- ------- -------
Accrued pension liability $(2,102) $(1,244) $(2,034) $(1,654)
======= ======= ======= =======
</TABLE>
CONTINGENCIES
The Company is subject to potential liability under government regulations and
various claims and legal actions which are pending or may be asserted. These
claims and legal actions have arisen in the ordinary course and conduct of the
Company's business and some are expected to be covered, at least partly, by
insurance. Estimated amounts for claims that are probable, can be reasonably
estimated and are not covered by insurance are reflected as liabilities of the
Company. The ultimate resolution of these claims is subject to many
uncertainties, and it is reasonably possible that some of the actions or
proceedings referred to above could be decided unfavorably to the Company.
Although the amount of liability at December 31, 1997 with respect to these
matters could not be ascertained with certainty, the Company believes that any
resulting liability should not materially affect the Company's consolidated
financial statements.
CURRENCY EFFECTS
The financial statements of the Company's non-U.S. operations are translated to
U.S. dollars for consolidation using exchange rates at period end for assets and
liabilities and average exchange rates during each reporting period for results
of operations. Net exchange gains or losses resulting from the translation of
foreign financial statements, the effect of exchange rate changes on
intercompany transactions of a long-term investment nature, and net exchange
rate gains and losses on foreign currency transactions that are designated as,
and are effective as, economic hedges of the net investment in a foreign entity
are recorded as a separate component of equity. These adjustments will affect
net income only upon sale or liquidation of the underlying non-U.S. investment.
Many of the Company's reporting entities conduct a portion of their business in
currencies other than the entity's functional currency. These transactions give
rise to receivables or payables that are denominated in currencies other
F-16
<PAGE>
than the entity's functional currency. Changes in the exchange rates between the
functional currency and the currency in which the transaction is denominated
result in currency transaction gains and losses that are included in the
determination of income. Currency exchange losses realized on business
transactions were $1.0 million in 1997, $0.2 million in 1996, and $0.1 million
in 1995.
The Company utilizes forward exchange contracts to hedge non-local currency
transactions and commitments. Gains and losses on forward exchange contracts
that hedge specific currency commitments are deferred and recognized in income
in the same period as the hedged transaction. Gains and losses on forward
contracts that do not hedge an identifiable currency commitment are included in
income as the gain or loss arises.
The market risk associated with forward exchange contracts is caused by
fluctuations in exchange rates subsequent to entering into the forward exchange
contracts. Forward exchange contracts outstanding at year-end 1997 were short-
term in nature and related to non-local currency transactions of the Company's
Japanese subsidiary. The equivalent U.S. dollar purchase amounts of all forward
contracts were $2.9 million, $6.2 million and $10.3 million as of December 31,
1997, 1996 and 1995, respectively. There were no sale amounts outstanding as of
December 31, 1997 and 1996. The equivalent U.S. dollar sale amount was $12.9
million as of December 31, 1995. Deferred unrealized gains and losses at
December 31, 1997, 1996 and 1995 were not significant.
STOCK INCENTIVE PLANS
In 1997, the Company established a long-term incentive plan for certain key
management and other personnel. The 1997 Long-term Incentive Plan provides that
up to 1,000,000 shares of common stock may be awarded through various stock and
stock related awards. For options awarded under the Plan, the option price
cannot be less than 100 percent of the fair market value of common stock at the
time the option is granted. Through December 31, 1997 the Company has granted
524,000 stock options under this plan.
In 1996, the Company established a Non-Employee Directors' Annual Retainer Stock
Plan enabling members of the Board of Directors who are not officers or
employees of the Company to receive common stock in lieu of all or a portion of
the annual cash retainer fee and to receive an automatic annual amount of 300
shares of common stock for services rendered. The Plan provides that up to
112,500 shares may be granted based on the fair market value of the common stock
at the date of issue. There have been 3,951 shares granted through December 31,
1997 under this plan.
In 1996, the Company established a Non-Employee Directors' Stock Option Plan
that provides for each of the Company's non-employee directors to receive an
automatic, annual option to purchase 6,750 shares of common stock. The Plan
provides that up to 750,000 shares may be granted based on the fair market value
of the common stock at the annual grant date. There have been 74,250 stock
options granted through December 31, 1997 under this plan.
All other stock option plans have been frozen and no further grants under the
frozen plans can be made. These plans are listed under "Former Plans No Longer
Granting Options."
F-17
<PAGE>
Most options become exercisable on a cumulative basis over a three year period
of service and are generally exercisable for a period not exceeding ten years
from the date of grant. At December 31, 1997 there were 476,000 and 680,250
shares of common stock available for future grant under the 1997 and 1996 stock
option plans, respectively.
The transactions under the stock option plans were as follows:
<TABLE>
<CAPTION>
1997 1996 Former Plans
Long-term Non-Employee No Longer
Incentive Directors' Granting
Plan Plan Options
=========== ============== ===============
<S> <C> <C> <C>
December 31, 1994 1,542,046
Granted at average price
of $16.00 per share 553,202
Expired or canceled at average
price of $14.03 per share (26,047)
Exercised at average price
of $10.17 per share (314,064)
----------- -------------- --------------
December 31, 1995 1,755,137
Granted at average price
of $24.44 per share 40,500 509,900
Expired or canceled at average
price of $15.50 per share (22,592)
Exercised at average price
of $11.70 per share (187,164)
----------- -------------- --------------
December 31, 1996 40,500 2,055,281
GRANTED AT AVERAGE PRICE
OF $34.26 PER SHARE 524,000 33,750
EXPIRED OR CANCELED AT AVERAGE
PRICE OF $21.10 PER SHARE (4,500) (6,241)
EXERCISED AT AVERAGE PRICE
of $10.96 per share (2,250) (413,186)
----------- -------------- --------------
December 31, 1997 524,000 67,500 1,635,854
=========== ============== ==============
Price range $34.41 $22.88 to 31.88 $4.8 to 25.00
WEIGHTED AVERAGE PRICE $34.41 $27.38 $17.10
=========== ============== ==============
EXERCISABLE - 11,250 1,124,200
=========== ============== ==============
</TABLE>
Information with respect to stock options outstanding at December 31, 1997 is as
follows:
<TABLE>
<CAPTION>
Weighted
Average Weighted
Remaining Average
Number Of Contractual Exercise
Price Range Options Life Price
========= =========== ========
<S> <C> <C> <C>
$ 4.83 to 9.67 86,965 1.2 $ 8.69
$11.08 to 13.92 564,416 2.9 $ 12.69
$16.00 to 18.00 513,377 7.8 $ 16.12
$22.88 to 25.00 504,846 8.8 $ 24.86
$31.88 to 34.41 557,750 9.8 $ 34.26
--------- ----------- --------
2,227,354 7.0 $ 21.48
========= =========== ========
</TABLE>
F-18
<PAGE>
Information with respect to stock options exercisable at December 31, 1997 is as
follows:
<TABLE>
<CAPTION>
Weighted
Year of Average
Option Number of Exercise
Expiration Options Price Price Range
========== ========= ======== ===============
<S> <C> <C> <C>
1998 123,730 $10.93 $ 4.83 to 13.92
1999 126,950 $12.25 $ 8.83 to 13.92
2000 171,001 $12.84 $12.12 to 25.00
2001 137,731 $12.33 $12.12 to 12.42
2002 92,469 $12.24 $12.12 to 12.25
2005 307,256 $16.00 $16.00
2006 176,313 $24.45 $18.00 to 25.00
- ---------- --------- -------- ---------------
All Years 1,135,450 $15.11 $ 4.83 to 25.00
========== ========= ======== ===============
</TABLE>
The Company elected the disclosure-only presentation of Statement of Financial
Accounting Standards No. 123, Accounting for Stock-Based Compensation ("SFAS No.
123"), in 1996 and, consequently, makes no charge against income in the
financial statements with respect to options granted at fair market value. To
measure stock-based compensation in accordance with SFAS No. 123, the fair value
of each option grant was estimated on the date of grant using the Black-Scholes
option-pricing model. The following table sets forth the assumptions used and
the pro forma net income and earnings per share resulting from applying SFAS No.
123.
<TABLE>
<CAPTION>
1997 1996 1995
======= ======= =======
<S> <C> <C> <C>
Net income (amounts in thousands)
As reported $32,235 $28,700 $22,277
Pro forma 30,501 27,918 22,149
Basic earnings per share (in dollars)
As reported $ 1.39 $ 1.25 $ .99
Pro forma $ 1.32 $ 1.22 $ .98
Diluted earnings per share (in dollars)
As reported $ 1.35 $ 1.22 $ .97
Pro forma $ 1.27 $ 1.19 $ .97
Risk-free interest rate 5.8% 6.1% 5.8%
Dividend yield 0.5% 0.6% 0.7%
Expected life in years 5 4 4
Volatility 29% 31% 31%
Weighted average remaining contractual
life in years 7.0 6.3 5.8
Weighted average fair value at date $ 11.93 $ 7.94 $ 4.96
of grant(in dollars)
======= ======= =======
</TABLE>
F-19
<PAGE>
QUARTERLY FINANCIAL INFORMATION
<TABLE>
<CAPTION>
(amounts in thousands, except per share data)
- -----------------------------------------------
Quarterly amounts are unaudited First Second Third Fourth Year
======= ======== ======= ======= ========
<S> <C> <C> <C> <C> <C>
1997:
Net sales $80,168 $ 84,556 $83,243 $83,000 $330,967
Net royalties 344 463 430 604 1,841
Cost of sales 36,116 39,069 38,126 39,236 152,547
Operating income 12,461 13,220 12,429 12,824 50,934
Net income 7,838 8,338 7,873 8,186 32,235
Basic earnings per share $ .34 $ .36 $ .34 $ .35 $ 1.39
Diluted earnings per share $ .33 $ .35 $ .33 $ .34 $ 1.35
Shares outstanding
Basic 22,984 23,137 23,243 23,316 23,171
Stock options 810 735 727 788 774
Diluted 23,794 23,872 23,970 24,104 23,945
Market price per share:
High $28 3/4 $ 30 $31 1/4 $35 7/8 $ 35 7/8
Low $24 1/4 $25 5/16 $26 7/8 $29 1/2 $ 24 1/4
======= ======== ======= ======= ========
1996:
Net sales $76,630 $ 77,430 $77,064 $78,331 $309,455
Net royalties - 134 425 325 884
Cost of sales 35,744 36,778 37,238 37,166 146,926
Gain on product line disposal - 2,569 - - 2,569
Operating income 10,916 13,352 10,621 11,212 46,101
Net income 6,682 8,295 6,631 7,092 28,700
Basic earnings per share $ .29 $ .36 $ .29 $ .31 $ 1.25
Diluted earnings per share $ .29 $ .35 $ .28 $ .30 $ 1.22
Shares outstanding
Basic 22,806 22,860 22,905 22,952 22,881
Stock options 492 574 669 701 623
Diluted 23,298 23,434 23,574 23,653 23,504
Market price per share:
High $21 1/3 $ 21 5/6 $25 3/4 $26 1/2 $ 26 1/2
Low $15 1/3 $ 18 $20 1/6 $21 1/8 $ 15 1/3
======= ======== ======= ======= ========
</TABLE>
F-20
<PAGE>
GEOGRAPHIC DATA
<TABLE>
<CAPTION>
(amounts in thousands) 1997 1996 1995
========= ========= =========
<S> <C> <C> <C>
Net sales:
North America $216,463 $193,468 $172,112
Intercompany (36,933) (31,809) (21,203)
-------- -------- --------
Trade sales 179,530 161,659 150,909
-------- -------- --------
Europe 107,089 106,598 100,220
Intercompany (1,407) (1,480) (1,673)
-------- -------- --------
Trade sales 105,682 105,118 98,547
-------- -------- --------
Pacific 45,859 45,042 24,129
Intercompany (104) (2,364) (1,353)
-------- -------- --------
Trade sales 45,755 42,678 22,776
-------- -------- --------
Net sales $330,967 $309,455 $272,232
======== ======== ========
Operating income:
North America $ 33,646 $ 24,798 $ 15,433
Europe 19,419 22,330 22,323
Pacific area 6,968 5,404 4,559
General corporate expense (9,099) (6,431) (8,163)
-------- -------- --------
Operating income $ 50,934 $ 46,101 $ 34,152
======== ======== ========
Assets:
North America $183,467 $150,627 $102,966
Europe 66,348 72,561 74,888
Pacific area 30,459 30,743 30,890
-------- -------- --------
Total assets $280,274 $253,931 $208,744
======== ======== ========
</TABLE>
Intercompany sales between areas are based on estimated market prices or on
amounts computed to provide reasonable profit to each unit. Operating income
represents net sales less expenses of operations. Certain expenses have been
allocated to the geographic segments based upon utilization percentages
developed by management. Certain amounts previously reported as general
corporate expenses in 1996 and 1995, primarily for research and development and
product management expenses, have been reclassified to geographic segments to be
consistent with the 1997 presentation. Sales and related income prior to
September 1995 to the Company's then-unconsolidated Japanese joint venture,
LTOKK, are included in the Pacific area.
F-21
<PAGE>
<TABLE>
<CAPTION>
INDEX TO EXHIBITS PAGE#
-----------------
<S> <C>
3(A) Certificate of Incorporation of the Registrant including
Amendment to Certificate of Incorporation dated April 17, 1987,
previously filed as Exhibit 3(A) to the Registrant's Annual Report on
Form 10-K for the year ended December 31, 1992, which is incorporated
herein by reference.
3(B) By-laws of the Registrant as amended and restated on April 16,
1991, previously filed as Exhibit 3(B) to the Registrant's Annual Report
on Form 10-K for the year ended December 31, 1991, which is incorporated
herein by reference.
4(A) Instruments defining the rights of security holders, including
indentures.
Registrant by this filing agrees, upon request, to file with
the Securities and Exchange Commission the instruments defining the
rights of holders of its long-term debt where the total amount of
securities authorized thereunder does not exceed 10% of the total assets
of registrant and its subsidiaries on a consolidated basis.
10(A) 1984 Stock Option Plan, previously filed as Exhibit 4.1 to the
Registrant's Registration Statement on Form S-8, No. 33-21807, dated May
12, 1988, SEC file no. 0-14991, which is incorporated herein by
reference.
10(B) Executive Supplemental Retirement Plan, previously filed as
Exhibit 10(B) to the Registrant's Annual Report on Form 10-K for the year
ended December 31, 1990, SEC file no. 0-14991, which is incorporated
herein by reference.
10(C) Executive Deferred Compensation Benefit Plan, previously filed as
Exhibit 10.8 to the Registrant's Registration Statement on Form S-1, No.
33-7993, dated October 1, 1986, which is incorporated herein by
reference.
10(D) Change-in-Control Agreement dated February 13, 1997, between the
Registrant and Dr. J. Stark Thompson regarding certain severance benefits
in the event of termination of employment following a change of control,
as defined in the agreement, previously filed as Exhibit 10.2 to the
Registrant's Quarterly Report on Form 10-Q for the quarter ended March
31, 1997, SEC file no. 0-14991, which is incorporated herein by
reference.
10(E) Change-in-Control Agreement dated February 13, 1997, between the
Registrant and Joseph C. Stokes, Jr. regarding certain severance benefits
in the event of termination of employment following a change of control,
as defined in the agreement, previously filed as Exhibit 10.3 to the
Registrant's Quarterly Report on Form 10-Q for the quarter ended March
31, 1997, SEC file no. 0-14991, which is incorporated herein by
reference.
</TABLE>
<PAGE>
<TABLE>
<S> <C>
10(F) Change-in-Control Agreement dated February 13, 1997, between the
Registrant and Thomas M. Coutts regarding certain severance benefits in
the event of termination of employment following a change of control, as
defined in the agreement, previously filed as Exhibit 10.1 to the
Registrant's Quarterly Report on Form 10-Q for the quarter ended March
31, 1997, SEC file no. 0-14991, which is incorporated herein by
reference.
10(G) Change-in-Control Agreement dated February 13, 1997, between the
Registrant and John V. Cooper regarding certain severance benefits in the
event of termination of employment following a change of control, as
defined in the agreement, previously filed as Exhibit 10.5 to the
Registrant's Quarterly Report on Form 10-Q for the quarter ended March
31, 1997, SEC file no. 0-14991, which is incorporated herein by
reference.
10(H) Executive Deferred Compensation Benefit Plan, previously filed as
Exhibit 10(H) to the Registrant's Annual Report on Form 10-K for the year
ended December 31, 1991, SEC file no. 0-14991, which is incorporated
herein by reference.
10(I) 1991 Stock Option Plan, previously filed as Exhibit 4 to the
Registrant's Registration Statement on Form S-8 No. 33-956, dated May 9,
1991, which is incorporated herein by reference.
10(J) 1995 Long-term Incentive Plan, previously filed as Exhibit 4 to the
Registrant's Registration Statement on Form S-8 No. 33-59741, dated June
1, 1995, which is incorporated herein by reference.
10(K) Change-in-Control Agreement dated February 13, 1997, between the
Registrant and John E. Leffler regarding certain severance benefits in
the event of termination of employment following a change of control, as
defined in the agreement, previously filed as Exhibit 10.4 to the
Registrant's Quarterly Report on Form 10-Q for the quarter ended March
31, 1997, SEC file no. 0-14991, which is incorporated herein by
reference.
10(L) 1996 Non-Employee Directors' Stock Option Plan, previously filed as
Exhibit 4(b) to the Registrant's Registration Statement on Form S-8
No. 333-03773, dated May 15, 1996, which is incorporated herein by
reference.
10(M) 1996 Non-Employee Directors' Annual Retainer Stock Plan,
previously filed as Exhibit 4(a) to the Registrant's Registration
Statement on Form S-8 No. 333-03773, dated May 15, 1996, which is
incorporated herein by reference.
</TABLE>
<PAGE>
<TABLE>
<S> <C>
10(N) Form of Employment Agreement effective February 13, 1997, between the
Registrant and certain executive officers of the Registrant regarding
certain severance benefits in the event of termination of employment
following a change in control, as defined in the agreement, previously
filed as Exhibit 10.6 to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended March 31, 1997, SEC file no. 0-14991, which is
incorporated herein by reference.
10(O) 1997 Long-term Incentive Plan, previously filed as Exhibit 4 to the
Registrant's Registration Statement on Form S-8 No. 333-28607, dated June
6, 1997, which is incorporated herein by reference.
21 Subsidiaries of the Registrant.
23 Consent of Independent Accountants.
27 Financial Data Schedule.
</TABLE>
<PAGE>
Exhibit 21
----------
SUBSIDIARIES OF THE REGISTRANT
------------------------------
The following table sets forth subsidiaries of Life Technologies, Inc. which are
included in the consolidated financial statements.
<TABLE>
<CAPTION>
Percentage Jurisdiction in
of Which Incorporated
Name Ownership or Organized
- ----------- ---------------- -------------------
<S> <C> <C>
Canadian Life Technologies, Inc. 100% Ontario
Laboratory Services Ltd. 100% New Zealand
Life Technologies A.G. 100% (A) Switzerland
Life Technologies A.S. 100% Denmark
Life Technologies B.V. 100% (A) Netherlands
Life Technologies do Brasil Ltda. 100% Brazil
Life Technologies Foreign Sales Corp. 100% Barbados
Life Technologies Holdings, Unlimited 100% Scotland
Life Technologies GmbH 100% (A) Germany
Life Technologies Investment Holdings,Inc. 100% Delaware, USA
Life Technologies Italia S.r.l. 100% Italy
Life Technologies Ltd. 100% (B) Scotland
Life Technologies Ltd. 100% New Zealand
Life Technologies Mauritius Ltd. 100% Mauritius
Life Technologies Overseas Ltd. 100% (B) Scotland
Life Technologies (Pacific) Ltd. 100% Hong Kong
Life Technologies Pty. Ltd. 100% Australia
Life Technologies S.A.R.L. 100% (A) France
Life Technologies Asia Pacific Inc. 100% Delaware, USA
N.V. Life Technologies S.A. 100% (A) Belgium
Serum Tech (unincorporated joint venture) 40% (C) Maryland, USA
Life Technologies Sweden AB 100% Sweden
Life Technologies S.A. 100% Spain
Life Technologies Uruguay, S.A. 100% Uruguay
Custom Primers, Inc. 100% California, USA
Life Technologies Oriental K.K. 80% Japan
Life Technologies GIBCO BRL Co., Ltd. 51% Republic of China,
(Taiwan)
Serum Technologies Holdings, Inc. 100% Delaware, USA
</TABLE>
(A) Owned by Life Technologies Overseas Ltd.
(B) Owned by Life Technologies Holdings, Unlimited
(C) Owned by Serum Technologies Holdings, Inc.
<PAGE>
Exhibit 23
----------
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the incorporation by reference in the registration statements of
Life Technologies, Inc. and subsidiaries on Form S-8, Registration No. 333-
28607, Registration No. 33-59741, Registration No. 33-21807 and Registration No.
33-956, and the Company's registration statement on Form S-3, Registration No.
33-29536, of our report dated January 23, 1998, on our audits of the
consolidated financial statements of Life Technologies, Inc. and subsidiaries as
of December 31, 1997 and 1996, and for the years ended December 31, 1997, 1996
and 1995, which report is included in this Annual Report on Form 10-K.
/s/ Coopers & Lybrand L.L.P.
----------------------------
McLean, Virginia
February 26, 1998
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET, INCOME STATEMENT AND EXHIBIT 11 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> DEC-31-1997
<CASH> 19,076
<SECURITIES> 0
<RECEIVABLES> 59,706
<ALLOWANCES> 1,610
<INVENTORY> 68,063
<CURRENT-ASSETS> 155,458
<PP&E> 151,368
<DEPRECIATION> 51,270
<TOTAL-ASSETS> 280,274
<CURRENT-LIABILITIES> 54,531
<BONDS> 4,564
0
0
<COMMON> 234
<OTHER-SE> 208,490
<TOTAL-LIABILITY-AND-EQUITY> 280,274
<SALES> 330,967
<TOTAL-REVENUES> 332,808
<CGS> 152,547
<TOTAL-COSTS> 152,547
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 70
<INCOME-PRETAX> 51,338
<INCOME-TAX> 18,481
<INCOME-CONTINUING> 32,235
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 32,235
<EPS-PRIMARY> 1.39
<EPS-DILUTED> 1.35
</TABLE>
